Fagron increases share capital through exercise subscription rights

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 29 September 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 355,000 new shares have been issued on 29 September 2025. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 506,745,841.93. The total number of shares with voting rights after the...

Nazareth, 29/09/2025 (informazione.news - comunicati stampa - salute e benessere)

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 29 September 2025 – 7PM CET

Fagron increases share capital through exercise subscription rights

Fagron announces that as a result of the exercise of subscription rights, 355,000 new shares have been issued on 29 September 2025.

In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 506,745,841.93. The total number of shares with voting rights after the issue amounts to 73,668,904 which is also the total number of voting rights (the ‘denominator’). The total number of rights (formerly known as warrants) to subscribe to not yet issued shares with voting rights amounts to 1,110,833.

Further information
Ignacio Artola
Global Investor Relations Leader
Tel. +34 670385795
ignacio.artola@fagron.com

About Fagron
Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in 35 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment